NEW YORK (GenomeWeb News) – Madison, Wis.-based Cellular Dynamics and Sittingbourne, England-based VivoMedica today said that they have launched a consortium to validate a human cell model and analysis system, based on the firms' technologies, for preclinical cardiotoxicity testing of drug candidates.

The firms said the consortium is being launched this week in France at the Safety Pharmacology Society 9th Annual Meeting. The firms hope to enlist pharmaceutical companies in validating the human cardiac model.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.